IONIS PHARMACEUTICALS INC·4

Apr 2, 7:43 PM ET

Devers Shannon L. 4

4 · IONIS PHARMACEUTICALS INC · Filed Apr 2, 2026

Research Summary

AI-generated summary of this filing

Updated

Ionis (IONS) EVP Shannon L. Devers Sells 6,193 Shares

What Happened

  • Shannon L. Devers, Executive Vice President and Chief Human Resources Officer of Ionis Pharmaceuticals (IONS), sold 6,193 shares in an open-market transaction on April 2, 2026. The filing reports a weighted-average sale price of $74.05 per share for proceeds of approximately $458,613.

Key Details

  • Transaction date: 2026-04-02.
  • Sale: 6,193 shares; weighted-average price reported $74.05; price range for the multiple trades was $73.62 to $74.2450.
  • Total reported proceeds: $458,613 (per the Form 4).
  • Footnote: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2025.
  • The filing states the weighted-average price and offers to provide a breakdown of shares sold at each price on request.
  • Shares owned after the transaction: not specified in the information provided in this summary filing.
  • Filing timeliness: Reported on April 2, 2026 (the same day as the transaction date listed), with no late-filing indication in the provided data.

Context

  • The sale was executed under a pre-established Rule 10b5-1 plan, which is commonly used to schedule sales in advance and may reflect routine disposition rather than a contemporaneous view on the company. This is a straightforward open‑market sale (code S) — not an option exercise, gift, or award.

Insider Transaction Report

Form 4
Period: 2026-04-02
Devers Shannon L.
EVP, Chief Human Resources Ofc
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-04-02$74.05/sh6,193$458,61316,348 total
Footnotes (2)
  • [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.2450 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Shannon Devers|2026-04-02

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT